Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Safehold enters its October 30 earnings print in a difficult spot. The stock has fallen 15% over the past month to $11.97, analysts are cutting targets across the board, and the Street's tone on the ground-lease model has shifted markedly more cautious in the past few weeks.
The analyst story is the most telling development this week. Citizens downgraded the stock on October 14, moving to Market Perform from Market Outperform. That followed RBC Capital lowering its target from $16 to $13 on October 9, while keeping a Sector Perform rating. Truist and Mizuho both trimmed targets to $13 and $14 respectively in late September. JP Morgan went further, cutting to Underweight in late September with a $14 target. Goldman Sachs remains the lone outright Buy, but even that desk lowered its target from $27 to $23 back in May. The consensus is now Hold across six firms, with one outperform and one fresh underweight. The mean price target of $16.44 sits well above the current price, though the trend in that figure has been consistently downward. The bear case is straightforward: dilution from the Brookfield joint venture, higher interest expense, and the 10-year Treasury move from roughly 4.70% in late August to above 5% in late September have all weighed on EPS estimates, now pegged at $1.58 for 2026. The bull case rests on the structural durability of the ground-lease model, credit seniority, and the eventual acquisition of building ownership at lease expiration, but those are long-duration arguments in a market demanding near-term clarity.
Options positioning has shifted sharply away from defensiveness in the last week, though not in the way one might expect as a stock falls. The put/call ratio has dropped to 1.34 from a 20-day average of 2.02, a move nearly 2.6 standard deviations below that mean. Over the prior month the PCR had been running well above 2, reaching as high as 2.47 in late September. The recent drop suggests call buying has picked up or put protection is being unwound, an unusual divergence from the bearish price action. The 52-week low on the PCR is 0.20, so positioning is far from outright bullish, but the shift is notable against the backdrop of falling prices and fresh analyst downgrades.
Short interest is a minor factor here rather than a central story. At 4.5% of the free float, it eased about 7.8% on the week as roughly 255,000 shares of short interest came off the books in early October, suggesting some covering rather than fresh accumulation. Borrow conditions remain loose. Availability is running at over 1,400% of short interest, meaning there are more than fourteen times as many shares available to borrow as are currently borrowed. The cost to borrow ticked up about 25% on the week to 0.64%, but in absolute terms that is still well within normal range for a stock of this size and liquidity. There is no squeeze dynamic present. Shorts are not crowded, and the borrow market is not signalling conviction in either direction.
The ownership structure is worth a brief note. Star Holdings sits at roughly 19% of shares outstanding, with no reported change since March. BlackRock added about 200,000 shares as of September 30, bringing its stake to 14%. T. Rowe Price holds 6.7% and added nearly 790,000 shares in the quarter to June. The only recent open-market insider trade on record was a director's sale of 9,500 shares at $14.56 in early September, worth around $138,000. It was not under a 10b5-1 plan, but it was a small position relative to the scale of institutional moves and carries limited informational weight on its own.
On the index rebalance radar, ORTEX puts the probability of a share decrease in the CRSP US Small index at the December 2026 Quarterly Review at 47%. At that probability, the call is essentially a coin flip, with a rank date of December 4 and a trade date of December 22. The associated selling flow would be around $10 million, roughly 2.1 days of normal volume. SAFE is described as within 0.0% of the 99.5% index edge, meaning the current price is sitting almost exactly at the boundary that determines the outcome.
With earnings on October 30, the key variable is less about the direction of originations and more about what management says on interest rate sensitivity and the trajectory of the Brookfield dilution. The prior quarter produced a 1% one-day decline and a 2.2% five-day decline after results, a muted reaction pattern that may not hold if the rate backdrop has deteriorated further since then.
See the live data behind this article on ORTEX.
Open SAFE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
